Pediatrics

Effectiveness is estimated at approximately 91% against any SARS-CoV-2 infection and approximately 85% effective against asymptomatic infection, analysis results show.

The decision is informed by the results of a phase 2b proof-of-concept study that assessed the immunogenicity and safety of the drug in healthy pregnant women and their infants.

During spring to fall 2020 related visits to emergency departments declined compared with a year earlier, study results show.

The investigators identified this in 9% of relapsed cases of pediatric acute myeloid leukemia, but it also was present in primary samples.

New study results show that rapidly adding pounds in the first and final months of gestation likely plays a key role in the development of excess fat tissue in female children and adolescents.

New study results show that of those who tested or were presumed positive for SARS-CoV-2, 44% developed neurological symptoms.

Study results show that unvaccinated pregnant women with the disease are more likely to experience poor childbirth outcomes, even if they did not have severe respiratory problems.

Study data showed that increased levels of infection, inflammation, and metabolic alterations frequently observed in people with depression and psychosis may be a cause rather than a consequence of these disorders.

The agency previously granted a priority review for the supplemental new drug application and also approved the drug in 2015 to treat adults.

GeneSight Mental Health Monitor finds that many struggle to know the difference between teenage behavior and a mental health challenge.

Study results show that these regimens increased the chances of treatment success among individuals aged 3 to 18 years compared to standard therapeutics.

Study results show that fetal cognitive development in the assessed areas was age-appropriate and there was no indication of infection.

Lomecel-B (Longeveron) is an investigational allogeneic, bone marrow-derived medicinal signaling cell medication that is being evaluated in a phase 2 trial.

In a report, the World Health Organization and a partner ask developers, funders, and investigators to accelerate developing a vaccination.

Study shows that about half the pediatric cases were symptomatic compared with 88% for individuals aged 18 years and older.

The results of a review by Murdoch Children’s Research Institute finds that pediatric patients who are vaccinated get protection from the long-term effects of the disease.

Investigators observed improvements in inflammation of the cornea and ocular itching among patients receiving Verkazia in both trials.

The condition is not preventable, but there are steps that can be taken to reduce LDL-C levels in children.

This data could offer additional insights into how the pandemic may be impacting the nation's children, according to the study authors.

The FDA has expanded its approval of short ragweed pollen allergen extract (Ragwitek; ALK) to include treatment for children and adolescents, starting at age 5 years, with short ragweed pollen-induced allergic rhinitis.

Despite significant decreases in 2020, a large number of adolescents less than 18 years of age continue to use e-cigarettes, with considerable adverse health effects, according to a presentation at the 2021 National Association of Pediatric Nurse Practitioners (NAPNAP) conference.

First approved by the FDA in 1989 for 2 rare eye muscle disorders, onabotulinumtoxinA (Botox; Allergan) was the world’s first approved botulinum toxin type A treatment.

Push continues for more access to EpiPens, but it is important to protect health care providers who administer the treatment.

Data show that children with cancer who are experiencing neighborhood poverty and rely on public health insurance have an increased risk of death with stem cell treatment.

Clinicians often reserve vigilance with drug-related issues for critically ill patients or older populations, while mistaking the resilience of childhood as a protective barrier.

A table showing recommended immunization schedules for child and adolescent patients.

Pharmacy Times will continue to bring readers the latest information on COVID-19 developments, in a variety of formats.

Risdiplam is the first at-home, orally administered treatment for spinal muscular atrophy in adults and children aged 2 months and older.

How did switching from name brand to generic cause a child’s death?

Staying up-to-date on immunizations is crucial to prevent outbreaks of vaccine-preventable diseases.